As previously mentioned, in recent years, there have been important clinical responses to CD19 CAR T-cell therapy against hematological tumors including ALL, chronic lymphocytic leukemia (CLL), and diffuse large B cell lymphoma, using second-generation receptors comprising either CD28 or 4-1BB [reviewed in Ref. Here, CD19 is linked to acute lymphoblastic leukemia.